Shares of Agilent Technologies, Inc. (NYSE:A) have received an average recommendation of “Buy” from the sixteen research firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $58.27.

A number of brokerages have recently commented on A. BidaskClub raised Agilent Technologies from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. Wells Fargo & Company raised Agilent Technologies from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $42.92 to $60.73 in a research report on Wednesday, July 12th. Deutsche Bank AG reissued a “buy” rating and set a $58.00 price objective (up from $56.00) on shares of Agilent Technologies in a research report on Sunday, April 2nd. Robert W. Baird boosted their price objective on Agilent Technologies from $57.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 24th. Finally, Cowen and Company boosted their price objective on Agilent Technologies from $53.00 to $62.00 and gave the stock a “market perform” rating in a research report on Tuesday, May 23rd.

Agilent Technologies (NYSE A) traded down 0.37% during mid-day trading on Tuesday, hitting $61.32. 148,532 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $58.94 and its 200-day moving average price is $52.92. The stock has a market cap of $19.70 billion, a PE ratio of 34.47 and a beta of 1.31. Agilent Technologies has a one year low of $42.92 and a one year high of $61.65.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Monday, May 22nd. The medical research company reported $0.58 EPS for the quarter, topping the Zacks’ consensus estimate of $0.48 by $0.10. Agilent Technologies had a return on equity of 16.49% and a net margin of 13.41%. The business had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the company posted $0.44 earnings per share. The business’s revenue for the quarter was up 8.1% on a year-over-year basis. On average, analysts forecast that Agilent Technologies will post $2.23 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 26th. Shareholders of record on Monday, July 3rd will be paid a $0.132 dividend. This represents a $0.53 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Thursday, June 29th. Agilent Technologies’s dividend payout ratio is currently 29.78%.

In other Agilent Technologies news, insider Patrick Kaltenbach sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $54.50, for a total value of $109,000.00. Following the completion of the sale, the insider now owns 42,132 shares in the company, valued at $2,296,194. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Mark Doak sold 21,851 shares of the business’s stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $60.00, for a total value of $1,311,060.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 152,119 shares of company stock valued at $8,932,719.

Several large investors have recently added to or reduced their stakes in the company. Skandinaviska Enskilda Banken AB publ boosted its stake in Agilent Technologies by 5.7% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 64,834 shares of the medical research company’s stock valued at $3,428,000 after buying an additional 3,489 shares during the period. British Columbia Investment Management Corp boosted its stake in Agilent Technologies by 96.7% in the first quarter. British Columbia Investment Management Corp now owns 357,983 shares of the medical research company’s stock valued at $18,927,000 after buying an additional 175,992 shares during the period. Garde Capital Inc. boosted its stake in Agilent Technologies by 4.2% in the fourth quarter. Garde Capital Inc. now owns 13,341 shares of the medical research company’s stock valued at $608,000 after buying an additional 539 shares during the period. Wesbanco Bank Inc. bought a new stake in Agilent Technologies during the first quarter valued at approximately $215,000. Finally, Creative Planning boosted its stake in Agilent Technologies by 6.3% in the first quarter. Creative Planning now owns 11,961 shares of the medical research company’s stock valued at $632,000 after buying an additional 710 shares during the period.

TRADEMARK VIOLATION NOTICE: This article was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/07/18/agilent-technologies-inc-nysea-given-consensus-rating-of-buy-by-brokerages.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.